Bookmark

Add to MyYahoo RSS

Rheumatrex, Methotrexate News

News on Rheumatrex, Methotrexate (generic) continually updated from thousands of sources around the net.

15 hrs ago | JD Supra

Humira Patent Invalid for Obviousness Type Double Patenting

In AbbVie Inc. v. Kennedy Institute of Rheumatology Trust, the Federal Circuit affirmed the district court's finding that a second patent covering AbbVie's Humira product is invalid under the doctrine of obviousness-type double patenting.

Comment?

Related Topix: Medicine, Rheumatology, Inventions, Science / Technology, Rheumatoid Arthritis, Healthcare Law, Law

Wed Aug 06, 2014

Hispanic Business

Findings on Nanoparticles Detailed by Investigators at Xiamen...

In this paper, we report a novel strategy of preparing methotrexate nanopartides based on chitosan and methoxypoly used as nanocarriers to enhance their targeting and prolong blood circulation."

Comment?

Related Topix: Medicine

Mon Jul 28, 2014

BioSpace

CHMP Issues Positive Opinion For Roche RA Drug Label Expansion

On 24 July 2014 , the Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal p roduct RoActemra .

Comment?

Related Topix: Marketing, Medicine

BioMed Central

Presence of the full-length KIR2DS4 gene reduces the chance of...

KIR genes coding for natural killer cell immunoglobulin-like receptors, KIR, influence the effector and regulatory function of NK cells as well as some subpopulations of T lymphocytes depending on presence of ligands .

Comment?

Related Topix: Rheumatoid Arthritis, Medicine, Health

Seeking Alpha

CHMP issues positive opinion for Roche RA drug label expansion

The EMA's Committee for Medicinal Products for Human Use issues a positive opinion supporting the approval of Roche's RoActemra/ Actemra as as treatment for patients with early rheumatoid arthritis not previously treated with methotrexate .

Comment?

Related Topix: Rheumatoid Arthritis, Medicine, Health, Opinion

•••
•••
•••
•••
•••
•••
•••